Foote R L, Morita A, Ebersold M J, Olsen K D, Lewis J E, Quast L M, Ferguson J A, O'Fallon W M
Division of Radiation Oncology, Mayo Clinic, Rochester, MN 55905.
Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):835-42. doi: 10.1016/0360-3016(93)90457-7.
We describe our experience with adjuvant radiation therapy in patients who underwent operation for esthesioneuroblastoma.
Between January 1951 and December 1990, 49 patients with esthesioneuroblastoma received their initial treatment at the Mayo Clinic. There were 27 male and 22 female patients; their ages ranged from 3 to 79 years (median, 54 years). The tumors were Kadish Stage A in 4 patients, Stage B in 13, Stage C in 29, and modified Kadish Stage D in three (cervical nodal or distant metastasis). The tumors were graded according to Hyams' classification. Treatment included gross total resection alone in 22 patients and gross total resection and postoperative adjuvant radiation therapy in 16. The patients treated with adjuvant radiation had a greater proportion of advanced-stage and high-grade tumors.
The 5-year actuarial overall survival, disease-free survival, and local control rates were 69.1% + 7.0%, 54.8% + 7.6%, and 65.3% + 7.4%, respectively. The only significant predictor for overall survival, disease-free survival, and local control was Hyams' grade. Local control was improved in patients who received postoperative adjuvant radiation even though this group of patients had more advanced and higher-grade tumors (5-year rate of local control was 85.9% + 9.3%, compared with 72.7% + 9.5% for those who had operation alone, p = 0.26).
Adjuvant radiation therapy for esthesioneuroblastoma improves local tumor control, particularly for high-grade and high-stage tumors. We recommend additional treatment with radiation (55.5 Gy) after complete resection of esthesioneuroblastoma.
我们描述了接受嗅神经母细胞瘤手术患者辅助放疗的经验。
1951年1月至1990年12月期间,49例嗅神经母细胞瘤患者在梅奥诊所接受了初始治疗。男性27例,女性22例;年龄范围为3至79岁(中位年龄54岁)。肿瘤Kadish分期为A期4例,B期13例,C期29例,改良Kadish分期D期3例(颈部淋巴结转移或远处转移)。肿瘤根据海姆斯分类法分级。治疗包括单纯全切除22例患者,全切除加术后辅助放疗16例。接受辅助放疗的患者中晚期和高级别肿瘤的比例更高。
5年精算总生存率、无病生存率和局部控制率分别为69.1%±7.0%、54.8%±7.6%和65.3%±7.4%。总生存、无病生存和局部控制的唯一显著预测因素是海姆斯分级。接受术后辅助放疗的患者局部控制得到改善,尽管该组患者肿瘤更晚期、级别更高(5年局部控制率为85.9%±9.3%,单纯手术患者为72.7%±9.5%,p = 0.26)。
嗅神经母细胞瘤辅助放疗可改善局部肿瘤控制,特别是对于高级别和高分期肿瘤。我们建议在嗅神经母细胞瘤完全切除后追加放疗(55.5 Gy)。